Connect with us

Health

Dermal Filler Market to Make Great Impact In Near Future

Published

on

By Modupe Gbadeyanka

Dermal filler is the non-invasive treatment for facial rejuvenation and are used to as anti-ageing agents. As people age, facial skin begins to lose its flexibility and natural hydration that helps support, shape and add volume to the face. This leads to wrinkles on the face, deep lines and sagging of the skin. Dermal fillers are injectable gels composed from either natural or synthetically derived materials like hyaluronic acid. Dermal fillers gently lift and pump up the skin to restore the lost collagen owing to aging process. Dermal fillers also enable the body to generate its own collagen which can help in giving a natural and youthful facial appearance. Dermal filler treatment is highly effective as its results last from seven to 26 months, depending upon the type of dermal filler used. Dermal filler treatment takes 25-50 minutes with or without local anesthesia which can vary according to the patient skin and physical condition.

Dermal FillerMarket: Drivers and Restraints

Increasing number of patient with various cosmetic skin problems such as scars, deep lines and wrinkles, which is rising due to the imbalance in diet, insomnia, stress and tension, are the major factors which is fueling demand for dermal fillers. Dermal filler treatment is fast and easy for various cosmetic problems with a minimal amount of discomfort and downtime. The main factor which limits the growth of the global dermal filler market is the high cost of treatment.

Dermal Filler Market: Segmentation

Global dermal fillermarket is classified on the basis of product type, therapeutic area and geography

Based on product type, the global dermal filler market is segmented into the following:

    Absorbable or Biodegradable

    Non-Absorbable or Non-Biodegradable

Based on therapeutic area, the global dermal filler market is segmented into the following:

    Wrinkles

    Deep Facial Lines

    Sagging Skin

    Scars

Dermal Filler Market: Overview

Dermal filler is the treatment which is used to cure the natural break down of collagen and elastin fibers as people age. This type of natural breakdown occurs owing to the factors such as sun exposure, poor diet, stress and smoking. Dermal fillers can be classified into absorbable and non-absorbable. Absorbable dermal filler treatment last six to 12 months whereas non-absorbable fillers can last for 4-6 years. Hyaluronic acid is used in the gels which are used as fillers in dermal filler treatment. A very tiny needle is used to inject the fillers into the targeted therapeutic areas of the patient body.

Dermal Filler Market: Region-wise Outlook

The global dermal filler market is expected to register a healthy CAGR for the forecast period. Depending on geographic region, global dermal filler market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. North America held largest share in the global market of dermal filler followed by Europe, Japan and Asia Pacific owing to high occurrence of several skin problems among the population, increasing number of dermatology patients and increasing application in acne scar treatments. The developing nations in APAC and MEA hold huge potential for growth in the global dermal filler market, due to its quick and accurate results without any risk on skin.

Dermal Filler Market: Key Players

Some of the key participating global players in dermal fillerglobal market are Allergan, Inc., Galderma, Merz Aesthetics, Cynosure, Syneron, AQTIS Medical, Bioha Laboratories, Suneva Medical and Cytophil, Inc.

Modupe Gbadeyanka is a fast-rising journalist with Business Post Nigeria. Her passion for journalism is amazing. She is willing to learn more with a view to becoming one of the best pen-pushers in Nigeria. Her role models are the duo of CNN's Richard Quest and Christiane Amanpour.

1 Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

NAFDAC Announces Recall of WAP Sensual Enhancement Capsules

Published

on

WAP Sensual Enhancement Capsules

By Aduragbemi Omiyale

The National Agency for Food and Drug Administration and Control (NAFDAC) has announced the recall of a sexual enhancement product known as WAP Sensual Enhancement Capsules.

In a statement on Monday, the Nigerian agency disclosed that the recall is due to “undeclared pharmaceutical ingredients” in the product, whose country of origin is unknown, but is marketed and distributed online in the US through eBay.

It was emphasised that the recall is being “voluntarily” made by the manufacturer, Best Supplements Best Prices Company.

The detection of the undeclared pharmaceutical ingredients was made by the US Food and Drug Administration (FDA).

Laboratory analysis by the US FDA revealed that the product contained undeclared sildenafil, tadalafil, and flibanserin, which were not mentioned on the product label. Such substances may include phosphodiesterase type-5 (PDE-5) inhibitors or related compounds commonly used for the treatment of erectile dysfunction, the statement by NAFDAC stated.

Sildenafil and tadalafil are ingredients in FDA-approved prescription drugs used to treat erectile dysfunction.

It was noted that these undeclared ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.

Flibanserin is the active ingredient in an FDA-approved prescription drug used to treat low sexual desire in women. Flibanserin can cause drowsiness, sedation, dangerously low blood pressure, and fainting, especially when combined with alcohol.

Consumers have been encouraged to report compromised products (medicines or medical devices) to the nearest NAFDAC office, call 0800-162-3322, or send an email to sf******@********ov.ng.

Continue Reading

Health

Tinubu Chooses Obi Adigwe Coordinator of Health Tech Data Analytics Office

Published

on

obi adigwe

By Modupe Gbadeyanka

Dr Obi Adigwe has been appointed as the pioneer National Coordinator of the National Health Technology and Data Analytics Office (NHTDAO).

The body was created by the Ministry of Health under the approval of President Bola Tinubu.

NHTDAO will be domiciled in the Office of the Coordinating Minister of Health and Social Welfare, a statement on Friday by the Special Adviser to the President on Information and Strategy, Mr Bayo Onanuga, stated.

The agency will serve as a meta-level national platform for coordinating the country’s digital-health agenda. It will reinforce, not replace, the existing statutory functions of relevant departments and agencies, it was emphasised.

The organisation will also harmonise and empower the public and private institutions across the health system, set the standards that connect them, and operationalise the National Digital Health Architecture, approved by the National Council on Health in November 2025.

It was stated that President Tinubu expects NHTDAO to accelerate Nigeria’s transition to a secure, interoperable and data-driven health system that improves outcomes for all citizens.

Mr Adigwe, as Director General of the National Institute for Pharmaceutical Research and Development, has leveraged science to catalyse interventions in artificial intelligence, translational research, and technology transfer.

He coordinated major projects, including the ¥300m Nanotechnology grant and the AFREXIMBank grant for Africa’s first API Training Facility. He led the roadmap development that underpinned an €18 million EU grant, the largest in Africa for the thematic area. During the last pandemic, Adigwe globally showcased African science by undertaking the world’s first analysis to debunk claims about the Covid Organics preparation.

The Office’s Steering Committee, which provides strategic direction and oversight, comprises:

  • Professor Muhammad Ali Pate, Coordinating Minister of Health and Social Welfare (Co-chair)
  • Mr Olaniyi Yusuf, Chairman of the Nigerian Economic Summit Group (Co-chair)
  • Dr Iziaq Adekunle Salako, Minister of State for Health and Social Welfare (Alternate Co-chair)
  • Ms Kachollom Daju, Permanent Secretary, Federal Ministry of Health and Social Welfare
  • Mr Idris Alubankudi Saliu, Special Adviser to the President on Technology and Digital Economy
  • Dr Muntaqa Umar-Sadiq, National Coordinator, SWAp Coordination Office
  • Dr Abdu Mukhtar, National Coordinator, Presidential Initiative to Unlock Healthcare Value Chain
  • Dr Muyi Aina, Executive Director, National Primary Health Care Development Agency
  • Dr Kelechi Ohiri, Director General, National Health Insurance Authority
  • Director, Health Planning, Research and Statistics, Ministry of Health and Social Welfare
  • National Information Technology Development Agency Representative
  • Six representatives of the State Commissioners of Health, one from each of the six geopolitical zones
  • Pharm Hamza Buhari, Stakeholder representing Industry and Community.
Continue Reading

Health

Lagos Commences Screening of Newborns for Sickle Cell Disease

Published

on

sickle cell disease screening Lagos

By Modupe Gbadeyanka

The Lagos State government has kicked off an initiative to ensure that every newborn is screened for Sickle Cell Disease within 48 to 72 hours after birth using a simple heel-prick test.

It was gathered that babies identified as being at risk will immediately be placed on preventive care while awaiting confirmatory testing.

The Head of the Haematology Department at the Alimosho General Hospital, Dr Olubukola Orolu, revealed that an estimated 150,000 babies are born annually with Sickle Cell Disease in Nigeria, giving the country one of the highest SCD burdens globally.

She, however, applauded the Lagos State Government and the Clinton Health Access Initiative (CHAI) for introducing the state-wide newborn screening programme, describing it as a major step towards reducing childhood deaths associated with the disease.

The commencement of this scheme coincides with the 2026 World Sickle Cell Day, themed Young Voices Rising for Sickle Cell Disease – Closing the Survival Gap: Equity in Sickle Cell Disease.

It highlights the importance of listening to the experiences and aspirations of young people living with Sickle Cell Disease.

Mrs Orolu noted that SCD warriors are increasingly breaking barriers as advocates, leaders, students and change-makers, adding that their voices have continued to reshape the narrative through advocacy for equitable, patient-centred healthcare, self-care and experience sharing.

She, therefore, called for equal access to quality healthcare, survival opportunities and dignity for everyone living with Sickle Cell Disease.

Also commenting, the chief executive of Alimosho General Hospital, Dr Akinyele Akinlade, described Sickle Cell Disease as an inherited blood disorder that is not contagious, noting that individuals living with the condition are more susceptible to infections.

He advised SCD warriors to stay well hydrated, avoid stress, and protect themselves from extreme cold or heat, as these are common triggers of sickle cell crises, adding that these preventive measures can significantly reduce the frequency and severity of crises.

One of the participants, Ms Borokini Zainab, an SCD warrior and student nurse, expressed appreciation to the organisers for the enlightenment programme.

Sharing her personal journey, she spoke about the challenges of balancing recurrent pain crises with her academic pursuits and personal life. Despite moments of frustration, she encouraged fellow warriors not to lose hope.

“Don’t let sickle cell put you down. Be encouraged from within. Don’t let your dreams be shattered because of this,” she said, adding that her personal experience with Sickle Cell Disease inspired her to pursue a career in nursing so she could support others living with the condition.

Continue Reading

Trending